Patient Care

Cardiac Resynchronization Therapy with Implantable Cardioverter Defibrillator Placement Decreases Heart Failure


 

Clinical question: Does cardiac resynchronization therapy (CRT) with biventricular pacing decrease cardiac events in patients with reduced ejection fraction (EF) and wide QRS complex but only mild cardiac symptoms?

Background: In patients with severely reduced EF, implantable cardioverter defibrillators (ICDs) have been shown to improve survival. Meanwhile, CRT decreases heart-failure-related hospitalizations for patients with advanced heart-failure symptoms, EF less than 35%, and intraventricular conduction delay. It is not as clear whether patients with less-severe symptoms benefit from CRT.

Study design: Randomized, controlled trial.

Setting: 110 medical centers in the U.S., Canada, and Europe.

Synopsis: This Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT) study randomly assigned 1,820 adults with EF less than 30%, New York Health Association Class I or II congestive heart failure, and in sinus rhythm with QRS greater than 130 msec to receive ICD with CRT or ICD alone. The primary endpoint was all-cause mortality or nonfatal heart-failure events. Average followup was 2.4 years.

A 34% reduction in the primary endpoint was found in the ICD-CRT group when compared with the ICD-only group, primarily due to a 41% reduction in heart-failure events. In a subgroup analysis, women and patients with QRS greater than 150 msec experienced particular benefit. Echocardiography one year after device implantation demonstrated significant reductions in left ventricular end-systolic and end-diastolic volume, and a significant increase in EF with ICD-CRT versus ICD-only (P<0.001).

Bottom line: Compared with ICD alone, CRT in combination with ICD prevented heart-failure events in relatively asymptomatic heart-failure patients with low EF and prolonged QRS.

Citation: Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361(14):1329-1338.

Recommended Reading

Neither Low-Dose Dopamine nor Low-Dose Nesiritide Improves Renal Dysfunction in Acute Heart Failure Patients
The Hospitalist
Hospital Strategies for Decreasing Readmissions for Heart Failure Patients
The Hospitalist
No Mortality Difference Associated with Pre-Operative Beta Blocker Use for Coronary Artery Bypass Grafting Without Recent Myocardial Infarction
The Hospitalist
Shorter Door-to-Balloon Time for Heart Attack Patients
The Hospitalist
Coordinated Care Approach May Be Best for Patients with Heart Failure
The Hospitalist
ACCF/AHA 2013 Guidelines for Managing Heart Failure
The Hospitalist
Cardiologists Help Lower Readmission Rates for Hospitalized Heart Failure Patients
The Hospitalist
American College of Physicians Releases Clinical Practice Guideline for Treating Anemia in Heart Disease Patients
The Hospitalist
Hospitalists Focus on Matters of the Heart
The Hospitalist
ACP Guidelines on Treatment of Anemia in Patients With Heart Disease
The Hospitalist
   Comments ()